PMID: 7536027Jan 1, 1995Paper

Secondary tumours following etoposide containing therapy for germ cell cancer

Annals of Oncology : Official Journal of the European Society for Medical Oncology
C BoshoffJ Ong

Abstract

Reports have implied etoposide as the cause of secondary leukaemia in patients treated for germ cell cancer. Between 1979 and 1992, 679 male patients with germ cell cancer received etoposide containing chemotherapy. Six of 679 patients developed acute myeloid leukaemia (relative risk 150; CI: 55-326). None of these patients had a primary mediastinal germ cell tumour and only 1 patient received previous radiotherapy. The median interval between the onset of cytotoxic treatment and the development of leukaemia was 27 months. The FAB M4 morphology was seen in 4 of 6 cases. The benefit of etoposide containing protocols outweigh the risk of leukaemia in patients with intermediate or high risk disease, however in patients with good risk disease non-etoposide containing protocols should be explored.

Citations

Nov 5, 1997·Journal of the National Cancer Institute·L B TravisJ D Boice
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C BokemeyerC Nichols
Dec 10, 1999·Seminars in Surgical Oncology·C KollmannsbergerC Bokemeyer
Dec 22, 1999·International Journal of Cancer. Journal International Du Cancer·C KollmannsbergerC Bokemeyer
Oct 29, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N F KrynetskaiaM V Relling
Jul 31, 2003·Drugs·Uzair B Chaudhary, Jason R Haldas
Aug 9, 2006·Current Opinion in Oncology·Daniel M Patterson, Gordon J S Rustin
Nov 11, 2006·International Journal of Cancer. Journal International Du Cancer·Lorenzo RichiardiPaul Brennan
Jun 30, 2010·Journal of the National Cancer Institute·Lois B TravisSophie D Fossa
Mar 16, 2011·Nature Reviews. Urology·Chunkit Fung, David J Vaughn
Jun 1, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S Culine, J P Droz
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A SmithD Vena
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S. -K. Tay, L. -K. Tan
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D T SchneiderU Göbel
Jun 10, 2000·British Journal of Haematology·C H Pui, M V Relling
Oct 16, 2004·Current Oncology Reports·Naveed SarwarMichael J Seckl
Sep 16, 2003·Clinical Obstetrics and Gynecology·Jason D Wright, David G Mutch
Mar 31, 2006·Pediatric Blood & Cancer·K J PiccinelliR Skinner
May 1, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·D M PattersonG J S Rustin
Oct 9, 2007·Nature Clinical Practice. Urology·Tim Oliver
Aug 2, 2012·International Journal of Environmental Research and Public Health·Sachiko Ezoe
Sep 4, 2020·Case Reports in Oncological Medicine·Ben Man Fei CheungKwok Keung Yuen
May 8, 2001·Medical and Pediatric Oncology·C A Felix
Nov 19, 2003·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Teri Vega-Stromberg
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard E LinkLouis R Kavoussi
Oct 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexandra W van den Belt-DuseboutFlora E van Leeuwen
Jan 1, 2005·Journal of Cancer Research and Clinical Oncology·J WiereckyC Bokemeyer
Aug 9, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alice BergaminiMichael J Seckl
Apr 1, 1996·Critical Reviews in Oncology/hematology·S CulineJ P Droz
Sep 28, 2000·Cancer Treatment Reviews·A NgO B Eden
May 27, 2021·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Giorgia MangiliAlice Bergamini
May 1, 1996·Cancer Treatment Reviews·S Joel
Jan 22, 2005·Critical Reviews in Oncology/hematology·Stefania GoriMaurizio Marangolo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Iowa Medicine : Journal of the Iowa Medical Society
J Glauber, G H Clamon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M A Cooper, L H Einhorn
© 2021 Meta ULC. All rights reserved